Cholesterol
Mayo Clinic study finds major gaps in genetic screening for inherited high cholesterol
An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya
A large Mayo Clinic study reports that current guidelines fail to detect nearly 90% of people with familial hypercholesterolemia, a common inherited cause of dangerously high cholesterol and early heart disease. Researchers analyzed exome data from more than 84,000 participants and found that most would not have been selected for standard genetic testing. Expanding routine DNA screening, they say, could help identify at-risk individuals earlier and prevent severe cardiovascular outcomes.
A small randomized crossover study found no meaningful differences in cholesterol or other short‑term cardiometabolic markers when healthy adults consumed either palmitic‑rich or stearic‑rich interesterified fats for six weeks apiece.
An Ruwaito ta hanyar AI An Binciki Gaskiya
A large-scale genetic analysis of about 1.09 million people suggests that lifelong, genetically lower cholesterol—specifically non‑HDL cholesterol—is associated with substantially reduced dementia risk. Using Mendelian randomization to emulate the effects of cholesterol‑lowering drug targets such as those for statins (HMGCR) and ezetimibe (NPC1L1), the study found up to an approximately 80% lower risk per 1 mmol/L reduction for some targets. ([research-information.bris.ac.uk](https://research-information.bris.ac.uk/en/publications/cholesterollowering-drug-targets-reduce-risk-of-dementia-mendelia?utm_source=openai))